Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Investigational New Drugs|May 11, 2010
Ascorbate/menadione-induced oxidative stress kills cancer cells that express normal or mutated forms of the oncogenic protein Bcr-Abl. An in vitro and in vivo mechanistic studyRaphaël Beck, Rozangela Curi Pedrosa, Nicolas Dejeans, et al.
European Journal of Immunology|February 19, 2009
Comparison of stable human Treg and Th clones by transcriptional profilingJulie Stockis, Wolfram Fink, Violaine François, et al.
American Journal of Respiratory Cell and Molecular Biology|January 21, 2006
B lymphocytes are critical for lung fibrosis control and prostaglandin E2 regulation in IL-9 transgenic miceMohammed Arras, Jamila Louahed, Vincent Simoen, et al.
Leukemia Research Reports|December 28, 2013
Prognostic impact of JAK2V617F mutation in myelodysplatic syndromes: A matched case control studyBenoit de Renzis, Veronique Mansat-De Mas, Eric Wattel, et al.
European Journal of Haematology|December 30, 2017
Disease and treatment characteristics of polycythemia vera patients in Belgium: Results from a scientific surveyTimothy Devos, Yves Beguin, Lucien Noens, et al.
British Journal of Haematology|September 22, 2009
Impaired up-regulation of polo-like kinase 2 in B-cell chronic lymphocytic leukaemia lymphocytes resistant to fludarabine and 2-chlorodeoxyadenosine: a potential marker of defective damage responseEmeline de Viron, Laurent Knoops, Thierry Connerotte, et al.
Blood|May 8, 2007
In vivo p53 response and immune reaction underlie highly effective low-dose radiotherapy in follicular lymphomaLaurent Knoops, Rick Haas, Sanne de Kemp, et al.
Blood|May 10, 2011
PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemiaMaria Kleppe, Jean Soulier, Vahid Asnafi, et al.
Gastroenterology|September 17, 2011
A feedback loop between the liver-enriched transcription factor network and miR-122 controls hepatocyte differentiationIlaria Laudadio, Isabelle Manfroid, Younes Achouri, et al.
The New England Journal of Medicine|March 2, 2012
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosisClaire Harrison, Jean-Jacques Kiladjian, Haifa Kathrin Al-Ali, et al.
Pageof 5